Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.43 |
| ▸ | RXRB | P28702 | 6/20 | 0.43 |
| ▸ | RXRG | P48443 | 6/20 | 0.43 |
| ▸ | CYP26B1 | Q9NR63 | 9/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 11/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613947 | 0.86 | RXRA (0.43) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL13613909 | 0.85 | RXRA (0.41) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL13614075 | 0.84 | PTGS2 (0.37) | PTGS1 | |
| SCHEMBL13613911 | 0.84 | RXRA (0.45) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL13613841 | 0.83 | CYP26A1 (0.36) | RXRARXRBCYP26B1CYP26A1HRH3 | |
| SCHEMBL13613900 | 0.83 | RARB (0.41) | RXRACYP26B1CYP26A1 | |
| SCHEMBL13613893 | 0.82 | RXRA (0.41) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL13613956 | 0.78 | ALDH1A1 (0.37) | RXRARXRBRXRGCYP26B1LMNA | |
| SCHEMBL13613919 | 0.76 | RXRA (0.44) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL13613918 | 0.75 | RXRA (0.36) | RXRARXRBRXRGCYP26B1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | RXRA 351/4885RXRB 407/4885RXRG 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.